Pyxis Oncology Inc 's Cash & cash equivalent grew by 17.88 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Pyxis Oncology Inc 's Quick Ratio to 2.79, Quick Ratio remained below Pyxis Oncology Inc average.

Within Major Pharmaceutical Preparations industry 302 other companies have achieved higher Quick Ratio than Pyxis Oncology Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 983 to 1380.

Explain Quick Ratio?
How much Cash & cash equivalents PYXS�s has?
What are PYXS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PYXS/financial-strength

https://api.csimarket.com/api/v1/companies/PYXS/fundamentals

https://api.csimarket.com/api/v1/companies/PYXS/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

PYXS Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	2.89 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-27.12 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	2.79	Subscribe	Subscribe	Subscribe	Subscribe
PYXS's Total Ranking	# 1380	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-27.42 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	17.88 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 303
Healthcare Sector	# 530
Overall Market	# 1380

Quick Ratio Statistics
High	Average	Low
15.46	7.87	1.72
(Jun 30 2023)		(Jun 30 2026)

Financial Statements
Pyxis Oncology Inc 's Current Liabilities	$ 20 Millions	Visit PYXS's Balance sheet
Pyxis Oncology Inc 's Cash & cash equivalent	$ 56 Millions	Visit PYXS's Balance sheet
Source of PYXS's Sales		Visit PYXS's Sales by Geography

Cumulative Pyxis Oncology Inc 's Quick Ratio

PYXS's Quick Ratio for the trailling 12 Months

PYXS Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	23 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-47.03 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	2.48	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1901	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	0.66 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-8.94 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to PYXS Financial Strength Comparisons >> Go to Compare PYXS Quick Ratio to its Competitors

On the trailing twelve months basis Due to cut in Current Liabilities in the Q3 2026 to $19.94 millions, cumulative Quick Ratio decreased to 2.48 below the Pyxis Oncology Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 438 other companies have achieved higher Quick Ratio than Pyxis Oncology Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2962 to 3858.

Explain Quick Ratio?
How much Cash & cash equivalents PYXS�s has?
What are PYXS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 439
Healthcare Sector	# 901
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
13.12	4.04	0.55
(Sep 30 2022)		(Mar 31 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Cytomx Therapeutics Inc	7.64	$ 347.980 Millions	$ 45.532 Millions
Atea Pharmaceuticals Inc	7.64	$ 191.199 Millions	$ 25.025 Millions
Braveheart Bio, Inc.	7.27	$ 121.291 Millions	$ 16.673 Millions
Viking Therapeutics Inc	7.17	$ 959.813 Millions	$ 133.897 Millions
Scynexis Inc	7.09	$ 47.165 Millions	$ 6.652 Millions
Lb Pharmaceuticals Inc	7.03	$ 215.075 Millions	$ 30.573 Millions
Zentalis Pharmaceuticals Inc	7.03	$ 228.893 Millions	$ 32.539 Millions
Quoin Pharmaceuticals Ltd	6.95	$ 33.184 Millions	$ 4.776 Millions
Vera Therapeutics Inc	6.89	$ 384.042 Millions	$ 55.775 Millions
Nuvation Bio Inc	6.73	$ 663.370 Millions	$ 98.559 Millions
Anaptysbio Inc	6.71	$ 230.319 Millions	$ 34.318 Millions
Coya Therapeutics Inc	6.64	$ 35.802 Millions	$ 5.395 Millions
Capricor Therapeutics inc	6.61	$ 197.581 Millions	$ 29.895 Millions
Arcturus Therapeutics Holdings Inc	6.52	$ 184.817 Millions	$ 28.345 Millions
Moonlake Immunotherapeutics	6.50	$ 379.704 Millions	$ 58.430 Millions
Kiora Pharmaceuticals Inc	6.47	$ 16.287 Millions	$ 2.519 Millions
Camp4 Therapeutics Corporation	6.27	$ 124.522 Millions	$ 19.865 Millions
Context Therapeutics Inc	6.26	$ 34.411 Millions	$ 5.501 Millions
Sagimet Biosciences inc	6.22	$ 236.397 Millions	$ 37.985 Millions
Bridgebio Oncology Therapeutics Inc	6.18	$ 315.331 Millions	$ 51.026 Millions
Cartesian Therapeutics Inc	6.12	$ 122.975 Millions	$ 20.088 Millions
Olema Pharmaceuticals Inc	5.98	$ 413.771 Millions	$ 69.233 Millions
Summit Therapeutics Inc	5.71	$ 629.899 Millions	$ 110.226 Millions
Nurix Therapeutics Inc	5.51	$ 720.458 Millions	$ 130.742 Millions
United Therapeutics Corporation	5.51	$ 3,439.800 Millions	$ 624.300 Millions
Immuneering Corporation	5.45	$ 58.776 Millions	$ 10.791 Millions
Rocket Pharmaceuticals Inc	5.22	$ 279.470 Millions	$ 53.508 Millions
Aquestive Therapeutics Inc	5.22	$ 90.349 Millions	$ 17.299 Millions
Sionna Therapeutics Inc	5.11	$ 83.878 Millions	$ 16.420 Millions
Gain Therapeutics inc	4.94	$ 11.698 Millions	$ 2.369 Millions

Date modified: 2026-11-08T19:40:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.